Inflammation-associated microsatellite alterations: Mechanisms and significance in the prognosis of patients with colorectal cancer

World Journal of Gastrointestinal Oncology

Volumn 10, Issue 1, 2018, Pages 1-14

  Koi, Minoru ^a   Tseng Rogenski, Stephanie S ^a   Carethers, John M ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Elevated microsatellite alterations at selected tetranucleotide repeats; Inflammation; Microsatellite instability; Microsatellite stable; Mismatch repair; MSH3

Indexed keywords

ANTIINFLAMMATORY AGENT; DNA MISMATCH REPAIR PROTEIN MSH2; GENOMIC DNA; MUTL PROTEIN HOMOLOG 1;

BIOCHEMISTRY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; COLORECTAL CANCER; CYTOPLASM; DNA DAMAGE; GERMLINE MUTATION; INFLAMMATION; METASTASIS; MICROFLORA; MICROSATELLITE INSTABILITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT;

EID: 85041947439     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v10.i1.1     Document Type: Review

References (126)

1. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337 [PMID: 22810696 DOI: 10.1038/nature11252]
2. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257 [PMID: 9823339]
3. Overman MJ, Kopetz S, Lonardi S, McDermott R, Leone F, Leach J, Lenz H, Hendlisz A, Morse M, Garcia-Alfonso P, Desai J, Hill A, Moss RA, Goldberg MV, Lin C, Tang H, Andre T. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol 2016; 34: 3501
4. Tseng-Rogenski SS, Hamaya Y, Choi DY, Carethers JM. Interleukin 6. alters localization of hMSH3, leading to DNA mismatch repair defects in colorectal cancer cells. Gastroenterology 2015; 148: 579-589 [PMID: 25461668 DOI: 10.1053/j.gastro.2014.11.027]
5. Carethers JM. Microsatellite Instability Pathway and EMAST in Colorectal Cancer. Curr Colorectal Cancer Rep 2017; 13: 73-80 [PMID: 28367107 DOI: 10.1007/s11888-017-0352-y]
6. Subramanian S, Madgula VM, George R, Mishra RK, Pandit MW, Kumar CS, Singh L. Triplet repeats in human genome: distribution and their association with genes and other genomic regions. Bioinformatics 2003; 19: 549-552 [PMID: 12651711 DOI: 10.1186/ gb-2003-4-2-r13]
7. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-649 [PMID: 9872311 DOI: 10.1038/25292]
8. Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, Järvinen H, Powell SM, Jen J, Hamilton SR. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260: 812-816 [PMID: 8484121 DOI: 10.1126/science.8484121]
9. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-819 [PMID: 8484122 DOI: 10.1126/science.8484122]
10. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363: 558-561 [PMID: 8505985 DOI: 10.1038/363558a0]
11. Parsons R, Li GM, Longley MJ, Fang WH, Papadopoulos N, Jen J, de la Chapelle A, Kinzler KW, Vogelstein B, Modrich P. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993; 75: 1227-1236 [PMID: 8261516 DOI: 10.1016/009 2-8674(93)90331-J]
12. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1994; 77: 1 p following 166 [PMID: 8156592 DOI: 10.1016/0092-8674(93) 90546-3]
13. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomäki P, Sistonen P, Aaltonen LA, Nyström-Lahti M. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75: 1215-1225 [PMID: 8261515 DOI: 10.1016/0092-867 4(93)90330-S]
14. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368: 258-261 [PMID: 8145827 DOI: 10.1038/368258a0]
15. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263: 1625-1629 [PMID: 8128251 DOI: 10.1126/ science.8128251]
16. Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371: 75-80 [PMID: 8072530 DOI: 10.1038/371075a0]
17. Palombo F, Gallinari P, Iaccarino I, Lettieri T, Hughes M, D'Arrigo A, Truong O, Hsuan JJ, Jiricny J. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 1995; 268: 1912-1914 [PMID: 7604265 DOI: 10.1126/science.7604265]
18. Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997; 17: 271-272 [PMID: 9354786 DOI: 10.1038/ ng1197-271]
19. Eshleman JR, Markowitz SD. Microsatellite instability in inherited and sporadic neoplasms. Curr Opin Oncol 1995; 7: 83-89 [PMID: 7696368 DOI: 10.1097/00001622-199507010-00013]
20. Kolodner RD, Tytell JD, Schmeits JL, Kane MF, Gupta RD, Weger J, Wahlberg S, Fox EA, Peel D, Ziogas A, Garber JE, Syngal S, Anton-Culver H, Li FP. Germ-line msh6 mutations in colorectal cancer families. Cancer Res 1999; 59: 5068-5074 [PMID: 10537275]
21. de Wind N, Dekker M, Berns A, Radman M, te Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 1995; 82: 321-330 [PMID: 7628020 DOI: 10.1016/0092-8674(95)90319-4]
22. Reitmair AH, Schmits R, Ewel A, Bapat B, Redston M, Mitri A, Waterhouse P, Mittrücker HW, Wakeham A, Liu B. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet 1995; 11: 64-70 [PMID: 7550317 DOI: 10.1038/ng0995-64]
23. Baker SM, Bronner CE, Zhang L, Plug AW, Robatzek M, Warren G, Elliott EA, Yu J, Ashley T, Arnheim N, Flavell RA, Liskay RM. Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell 1995; 82: 309-319 [PMID: 7628019 DOI: 10.1016/0092-8674(95)90318-6]
24. Edelmann W, Yang K, Umar A, Heyer J, Lau K, Fan K, Liedtke W, Cohen PE, Kane MF, Lipford JR, Yu N, Crouse GF, Pollard JW, Kunkel T, Lipkin M, Kolodner R, Kucherlapati R. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 1997; 91: 467-477 [PMID: 9390556 DOI: 10.1016/S0092-8674(00)80433-X]
25. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, Boland CR. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 1994; 54: 4308-4312 [PMID: 8044777]
26. Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD, Boland CR, Barrett JC, Kunkel TA. Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 1997; 57: 3949-3955 [PMID: 9307278]
27. Watanabe Y, Haugen-Strano A, Umar A, Yamada K, Hemmi H, Kikuchi Y, Takano S, Shibata Y, Barrett JC, Kunkel TA, Koi M. Complementation of an hMSH2 defect in human colorectal carcinoma cells by human chromosome 2 transfer. Mol Carcinog 2000; 29: 37-49 [PMID: 11020245 DOI: 10.1002/1098-2744(20000 9)29:13.0.CO;2-2]
28. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95: 6870-6875 [PMID: 9618505 DOI: 10.1073/pnas.95.12.6870]
29. Halford S, Sasieni P, Rowan A, Wasan H, Bodmer W, Talbot I, Hawkins N, Ward R, Tomlinson I. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Res 2002; 62: 53-57 [PMID: 11782358]
30. Laiho P, Launonen V, Lahermo P, Esteller M, Guo M, Herman JG, Mecklin JP, Järvinen H, Sistonen P, Kim KM, Shibata D, Houlston RS, Aaltonen LA. Low-level microsatellite instability in most colorectal carcinomas. Cancer Res 2002; 62: 1166-1170 [PMID: 11861399]
31. Watson MM, Berg M, Søreide K. Prevalence and implications of elevated microsatellite alterations at selected tetranucleotides in cancer. Br J Cancer 2014; 111: 823-827 [PMID: 24691426 DOI: 10.1038/bjc.2014.167]
32. Haugen AC, Goel A, Yamada K, Marra G, Nguyen TP, Nagasaka T, Kanazawa S, Koike J, Kikuchi Y, Zhong X, Arita M, Shibuya K, Oshimura M, Hemmi H, Boland CR, Koi M. Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res 2008; 68: 8465-8472 [PMID: 18922920 DOI: 10.1158/0008-5472.CAN-08-0002]
33. Yamada K, Kanazawa S, Koike J, Sugiyama H, Xu C, Funahashi K, Boland CR, Koi M, Hemmi H. Microsatellite instability at tetranucleotide repeats in sporadic colorectal cancer in Japan. Oncol Rep 2010; 23: 551-561 [PMID: 20043121]
34. Lee SY, Chung H, Devaraj B, Iwaizumi M, Han HS, Hwang DY, Seong MK, Jung BH, Carethers JM. Microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasias. Gastroenterology 2010; 139: 1519-1525 [PMID: 20708618 DOI: 10.1053/j.gastro.2010.08.001]
35. Campregher C, Schmid G, Ferk F, Knasmüller S, Khare V, Kortüm B, Dammann K, Lang M, Scharl T, Spittler A, Roig AI, Shay JW, Gerner C, Gasche C. MSH3-deficiency initiates EMAST without oncogenic transformation of human colon epithelial cells. PLoS One 2012; 7: e50541 [PMID: 23209772 DOI: 10.1371/journal. pone.0050541]
36. Tseng-Rogenski SS, Chung H, Wilk MB, Zhang S, Iwaizumi M, Carethers JM. Oxidative stress induces nuclear-to-cytosol shift of hMSH3, a potential mechanism for EMAST in colorectal cancer cells. PLoS One 2012; 7: e50616 [PMID: 23226332 DOI: 10.1371/ journal.pone.0050616]
37. Carethers JM. Hereditary, sporadic and metastatic colorectal cancer are commonly driven by specific spectrums of defective DNA mismatch repair components. Trans Am Clin Climatol Assoc 2016; 127: 81-97 [PMID: 28066040]
38. Hsieh P, Zhang Y. The Devil is in the details for DNA mismatch repair. Proc Natl Acad Sci USA 2017; 114: 3552-3554 [PMID: 28356513 DOI: 10.1073/pnas.1702747114]
39. Gupta S, Gellert M, Yang W. Mechanism of mismatch recognition revealed by human MutSß bound to unpaired DNA loops. Nat Struct Mol Biol 2011; 19: 72-78 [PMID: 22179786 DOI: 10.1038/ nsmb.2175]
40. You JF, Buhard O, Ligtenberg MJ, Kets CM, Niessen RC, Hofstra RM, Wagner A, Dinjens WN, Colas C, Lascols O, Collura A, Flejou JF, Duval A, Hamelin R. Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats. Br J Cancer 2010; 103: 1840-1845 [PMID: 21081928 DOI: 10.1038/sj.bjc.6605988]
41. Kantelinen J, Kansikas M, Korhonen MK, Ollila S, Heinimann K, Kariola R, Nyström M. MutSbeta exceeds MutSalpha in dinucleotide loop repair. Br J Cancer 2010; 102: 1068-1073 [PMID: 20160730 DOI: 10.1038/sj.bjc.6605531]
42. Adam R, Spier I, Zhao B, Kloth M, Marquez J, Hinrichsen I, Kirfel J, Tafazzoli A, Horpaopan S, Uhlhaas S, Stienen D, Friedrichs N, Altmüller J, Laner A, Holzapfel S, Peters S, Kayser K, Thiele H, Holinski-Feder E, Marra G, Kristiansen G, Nöthen MM, Büttner R, Möslein G, Betz RC, Brieger A, Lifton RP, Aretz S. Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. Am J Hum Genet 2016; 99: 337-351 [PMID: 27476653 DOI: 10.1016/ j.ajhg.2016.06.015]
43. Devaraj B, Lee A, Cabrera BL, Miyai K, Luo L, Ramamoorthy S, Keku T, Sandler RS, McGuire KL, Carethers JM. Relationship of EMAST and microsatellite instability among patients with rectal cancer. J Gastrointest Surg 2010; 14: 1521-1528 [PMID: 20844976 DOI: 10.1007/s11605-010-1340-6]
44. Brentnall TA, Crispin DA, Bronner MP, Cherian SP, Hueffed M, Rabinovitch PS, Rubin CE, Haggitt RC, Boland CR. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res 1996; 56: 1237-1240 [PMID: 8640805]
45. Ozaki K, Nagasaka T, Notohara K, Kambara T, Takeda M, Sasamoto H, Jass JR, Tanaka N, Matsubara N. Heterogeneous microsatellite instability observed within epithelium of ulcerative colitis. Int J Cancer 2006; 119: 2513-2519 [PMID: 16929496 DOI: 10.1002/ijc.22095]
46. Munakata K, Koi M, Leconte P, Kitajima T, Tseng-Rogenski S, Uemura M, Mizushima T, Carethers JM. Loss of MSH3 and Subsequent EMAST Determines the Pathological Significance of MSI-L in Ulcerative Colitis. Gastroenterology 2016; 150: S962 [DOI: 10.1016/S0016-5085(16)33256-5]
47. Kohonen-Corish MR, Daniel JJ, Chan C, Lin BP, Kwun SY, Dent OF, Dhillon VS, Trent RJ, Chapuis PH, Bokey EL. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J Clin Oncol 2005; 23: 2318-2324 [PMID: 15800322 DOI: 10.1200/JCO.2005.00.109]
48. Wright CM, Dent OF, Newland RC, Barker M, Chapuis PH, Bokey EL, Young JP, Leggett BA, Jass JR, Macdonald GA. Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma. Gut 2005; 54: 103-108 [PMID: 15591513 DOI: 10.1136/gut2003.034579]
49. Lee SY, Kim DW, Lee HS, Ihn MH, Oh HK, Min BS, Kim WR, Huh JW, Yun JA, Lee KY, Kim NK, Lee WY, Kim HC, Kang SB. Low-Level Microsatellite Instability as a Potential Prognostic Factor in Sporadic Colorectal Cancer. Medicine (Baltimore) 2015; 94: e2260 [PMID: 26683947 DOI: 10.1097/MD.0000000000002260]
50. Azzoni C, Bottarelli L, Cecchini S, Silini EM, Bordi C, Sarli L. Sporadic colorectal carcinomas with low-level microsatellite instability: a distinct subgroup with specific clinicopathological and molecular features. Int J Colorectal Dis 2011; 26: 445-453 [PMID: 21336644 DOI: 10.1007/s00384-011-1133-8]
51. Garcia M, Choi C, Kim HR, Daoud Y, Toiyama Y, Takahashi M, Goel A, Boland CR, Koi M. Association between recurrent metastasis from stage II and III primary colorectal tumors and moderate microsatellite instability. Gastroenterology 2012; 143: 48-50.e1 [PMID: 22465427 DOI: 10.1053/j.gastro.2012.03.034]
52. Carethers JM, Koi M, Tseng-Rogenski SS. EMAST is a Form of Microsatellite Instability That is Initiated by Inflammation and Modulates Colorectal Cancer Progression. Genes (Basel) 2015; 6: 185-205 [PMID: 25836926 DOI: 10.3390/genes6020185]
53. Koi M, Garcia M, Choi C, Kim HR, Koike J, Hemmi H, Nagasaka T, Okugawa Y, Toiyama Y, Kitajima T, Imaoka H, Kusunoki M, Chen YH, Mukherjee B, Boland CR, Carethers JM. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis. Gastroenterology 2016; 150: 944-955 [PMID: 26752111 DOI: 10.1053/j.gastro.2015.12.032]
54. Cortes-Ciriano I, Lee S, Park WY, Kim TM, Park PJ. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun 2017; 8: 15180 [PMID: 28585546 DOI: 10.1038/ ncomms15180]
55. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101: 256-266 [PMID: 19211452 DOI: 10.1093/ jnci/djn485]
56. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternateday, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013; 159: 77-85 [PMID: 23856681 DOI: 10.7326/0003-4819-159-2-201307160-000 02]
57. Frouws MA, van Herk-Sukel MPP, Maas HA, Van de Velde CJH, Portielje JEA, Liefers GJ, Bastiaannet E. The mortality reducing effect of aspirin in colorectal cancer patients: Interpreting the evidence. Cancer Treat Rev 2017; 55: 120-127 [PMID: 28359968 DOI: 10.1016/j.ctrv.2016.12.008]
58. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-884 [PMID: 16943400 DOI: 10.1056/NEJMoa061355]
59. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885-895 [PMID: 16943401 DOI: 10.1056/NEJMoa061652]
60. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG; APPROVe Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131: 1674-1682 [PMID: 17087947 DOI: 10.1053/ j.gastro.200608.079]
61. Yamauchi T, Watanabe M, Hasegawa H, Nishibori H, Ishii Y, Tatematsu H, Yamamoto K, Kubota T, Kitajima M. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer. Anticancer Res 2003; 23: 245-249 [PMID: 12680220]
62. Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, Kwong E, Evans JF, Wolfe MM. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003; 63: 586-592 [PMID: 12566300]
63. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007; 356: 2131-2142 [PMID: 17522398 DOI: 10.1056/NEJMoa067208]
64. Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RL, Lemmens VE, van Herk-Sukel MP, van Wezel T, Fodde R, Kuppen PJ, Morreau H, van de Velde CJ, Liefers GJ. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med 2014; 174: 732-739 [PMID: 24687028 DOI: 10.1001/jamainternmed.2014.511]
65. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596-1606 [PMID: 23094721 DOI: 10.1056/NEJMoa1207756]
66. Gray RT, Cantwell MM, Coleman HG, Loughrey MB, Bankhead P, McQuaid S, O'Neill RF, Arthur K, Bingham V, McGready C, Gavin AT, Cardwell CR, Johnston BT, James JA, Hamilton PW, Salto-Tellez M, Murray LJ. Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study. Clin Transl Gastroenterol 2017; 8: e91 [PMID: 28448072 DOI: 10.1038/ctg.2017.18]
67. Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst 2014; 107: 345 [PMID: 25432409 DOI: 10.1093/jnci/dju345]
68. Ma X, Aoki T, Tsuruyama T, Narumiya S. Definition of Prostaglandin E2-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth. Cancer Res 2015; 75: 2822-2832 [PMID: 26018088 DOI: 10.1158/0008-5472]
69. Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik B, Galon J, Trajanoski Z. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol 2015; 16: 64 [PMID: 25853550 DOI: 10.1186/s13059-015-0620-6]
70. Becht E, de Reyniès A, Giraldo NA, Pilati C, Buttard B, Lacroix L, Selves J, Sautès-Fridman C, Laurent-Puig P, Fridman WH. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clin Cancer Res 2016; 22: 4057-4066 [PMID: 26994146 DOI: 10.1158/1078-0432.CCR-15-2879]
71. Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Quezada SA, Sahai E, Reis e Sousa C. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell 2015; 162: 1257-1270 [PMID: 26343581 DOI: 10.1016/j.cell.2015.08.015]
72. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767 [PMID: 2188735 DOI: 10.10 16/0092-8674(90)90186-I]
73. Ahrendt SA, Decker PA, Doffek K, Wang B, Xu L, Demeure MJ, Jen J, Sidransky D. Microsatellite instability at selected tetranucleotide repeats is associated with p53 mutations in nonsmall cell lung cancer. Cancer Res 2000; 60: 2488-2491 [PMID: 10811129]
74. Li J, Koike J, Kugoh H, Arita M, Ohhira T, Kikuchi Y, Funahashi K, Takamatsu K, Boland CR, Koi M, Hemmi H. Down-regulation of MutS homolog 3 by hypoxia in human colorectal cancer. Biochim Biophys Acta 2012; 1823: 889-899 [PMID: 22343000 DOI: 10.1016/ j.bbamcr.2012.01.017]
75. Robles AI, Traverso G, Zhang M, Roberts NJ, Khan MA, Joseph C, Lauwers GY, Selaru FM, Popoli M, Pittman ME, Ke X, Hruban RH, Meltzer SJ, Kinzler KW, Vogelstein B, Harris CC, Papadopoulos N. Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. Gastroenterology 2016; 150: 931-943 [PMID: 26764183 DOI: 10.1053/j.gastro.2015.12.036]
76. Yaeger R, Shah MA, Miller VA, Kelsen JR, Wang K, Heins ZJ, Ross JS, He Y, Sanford E, Yantiss RK, Balasubramanian S, Stephens PJ, Schultz N, Oren M, Tang L, Kelsen D. Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. Gastroenterology 2016; 151: 278-287. e6 [PMID: 27063727 DOI: 10.1053/j.gastro.2016.04.001]
77. Brennan CA, Garrett WS. Gut Microbiota, Inflammation, and Colorectal Cancer. Annu Rev Microbiol 2016; 70: 395-411 [PMID: 27607555 DOI: 10.1146/annurev-micro-102215-095513]
78. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe 2014; 15: 317-328 [PMID: 24629338 DOI: 10.1016/ j.chom.2014.02.007]
79. McCoy AN, Araújo-Pérez F, Azcárate-Peril A, Yeh JJ, Sandler RS, Keku TO. Fusobacterium is associated with colorectal adenomas. PLoS One 2013; 8: e53653 [PMID: 23335968 DOI: 10.1371/journal. pone.0053653]
80. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, El-Omar EM, Brenner D, Fuchs CS, Meyerson M, Garrett WS. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013; 14: 207-215 [PMID: 23954159 DOI: 10.1016/j.chom.2013.07.007]
81. Ito M, Kanno S, Nosho K, Sukawa Y, Mitsuhashi K, Kurihara H, Igarashi H, Takahashi T, Tachibana M, Takahashi H, Yoshii S, Takenouchi T, Hasegawa T, Okita K, Hirata K, Maruyama R, Suzuki H, Imai K, Yamamoto H, Shinomura Y. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer 2015; 137: 1258-1268 [PMID: 25703934 DOI: 10.1002/ijc.29488]
82. Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, An B, Shureiqi I, Toyota M, Kondo Y, Estécio MR, Issa JP. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 2014; 74: 1311-1318 [PMID: 24385213 DOI: 10.1158/0008-5472. CAN-13-1865]
83. Nosho K, Sukawa Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, Kanno S, Yamamoto I, Ishigami K, Igarashi H, Maruyama R, Imai K, Yamamoto H, Shinomura Y. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol 2016; 22: 557-566 [PMID: 26811607 DOI: 10.3748/wjg.v22.i2.557]
84. Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M, Kostic AD, Giannakis M, Bullman S, Milner DA, Baba H, Giovannucci EL, Garraway LA, Freeman GJ, Dranoff G, Garrett WS, Huttenhower C, Meyerson M, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 2016; 65: 1973-1980 [PMID: 26311717 DOI: 10.1136/gutjnl-2015-310101]
85. Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N, Chen Y, Chen H, Hong J, Zou W, Fang JY. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell 2017; 170: 548-563.e16 [PMID: 28753429 DOI: 10.1016/j.cell.2017.07.008]
86. Kawakami H, Zaanan A, Sinicrope FA. Implications of mismatch repair-deficient status on management of early stage colorectal cancer. J Gastrointest Oncol 2015; 6: 676-684 [PMID: 26697201 DOI: 10.3978/j.issn.2078-6891.2015.065]
87. Suzuki S, Iwaizumi M, Tseng-Rogenski S, Hamaya Y, Miyajima H, Kanaoka S, Sugimoto K, Carethers JM. Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status. Cancer Biol Ther 2016; 17: 760-768 [PMID: 27115207 DOI: 10.1080/15384047.2016.1178430]
88. Toprak NU, Yagci A, Gulluoglu BM, Akin ML, Demirkalem P, Celenk T, Soyletir G. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect 2006; 12: 782-786 [PMID: 16842574 DOI: 10.1111/ j.1469-0691.2006.01494.x]
89. Boleij A, Hechenbleikner EM, Goodwin AC, Badani R, Stein EM, Lazarev MG, Ellis B, Carroll KC, Albesiano E, Wick EC, Platz EA, Pardoll DM, Sears CL. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis 2015; 60: 208-215 [PMID: 25305284 DOI: 10.1093/cid/ ciu787]
90. Purcell RV, Pearson J, Aitchison A, Dixon L, Frizelle FA, Keenan JI. Colonization with enterotoxigenic Bacteroides fragilis is associated with early-stage colorectal neoplasia. PLoS One 2017; 12: e0171602 [PMID: 28151975 DOI: 10.1371/journal.pone.0171602]
91. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CL. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009; 15: 1016-1022 [PMID: 19701202 DOI: 10.1038/ nm.2015]
92. Sears CL, Geis AL, Housseau F. Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J Clin Invest 2014; 124: 4166-4172 [PMID: 25105360 DOI: 10.1172/ JCI72334]
93. Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012; 338: 120-123 [PMID: 22903521 DOI: 10.1126/science.1224820]
94. Bonnet M, Buc E, Sauvanet P, Darcha C, Dubois D, Pereira B, Déchelotte P, Bonnet R, Pezet D, Darfeuille-Michaud A. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res 2014; 20: 859-867 [PMID: 24334760 DOI: 10.1158/1078-0432.CCR-13-1343]
95. Tomkovich S, Yang Y, Winglee K, Gauthier J, Mühlbauer M, Sun X, Mohamadzadeh M, Liu X, Martin P, Wang GP, Oswald E, Fodor AA, Jobin C. Locoregional Effects of Microbiota in a Preclinical Model of Colon Carcinogenesis. Cancer Res 2017; 77: 2620-2632 [PMID: 28416491 DOI: 10.1158/0008-5472.CAN-16-3472]
96. Scott TA, Quintaneiro LM, Norvaisas P, Lui PP, Wilson MP, Leung KY, Herrera-Dominguez L, Sudiwala S, Pessia A, Clayton PT, Bryson K, Velagapudi V, Mills PB, Typas A, Greene NDE, Cabreiro F. Host-Microbe Co-metabolism Dictates Cancer Drug Efficacy in C. elegans. Cell 2017; 169: 442-456.e18 [PMID: 28431245 DOI: 10.1016/j.cell.2017.03.040]
97. Sugawara N, Pâques F, Colaiácovo M, Haber JE. Role of Saccharomyces cerevisiae Msh2 and Msh3 repair proteins in doublestrand break-induced recombination. Proc Natl Acad Sci USA 1997; 94: 9214-9219 [PMID: 9256462 DOI: 10.1073/pnas.94.17.9214]
98. Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, van Oers J, Edelmann W, Heukamp LC, Reinhardt HC. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov 2014; 4: 592-605 [PMID: 24556366 DOI: 10.1158/2159-8290]
99. Burdova K, Mihaljevic B, Sturzenegger A, Chappidi N, Janscak P. The Mismatch-Binding Factor MutSß Can Mediate ATR Activation in Response to DNA Double-Strand Breaks. Mol Cell 2015; 59: 603-614 [PMID: 26212458 DOI: 10.1016/j.molcel.2015.06.026]
100. Dietlein F, Thelen L, Reinhardt HC. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet 2014; 30: 326-339 [PMID: 25017190 DOI: 10.1016/ j.tig.2014.06.003]
101. Moudry P, Watanabe K, Wolanin KM, Bartkova J, Wassing IE, Watanabe S, Strauss R, Troelsgaard Pedersen R, Oestergaard VH, Lisby M, Andújar-Sánchez M, Maya-Mendoza A, Esashi F, Lukas J, Bartek J. TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity. J Cell Biol 2016; 212: 281-288 [PMID: 26811421 DOI: 10.1083/jcb.201507042]
102. Lee JH, Paull TT. Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science 2004; 304: 93-96 [PMID: 15064416 DOI: 10.1126/science.1091496]
103. Sedelnikova OA, Redon CE, Dickey JS, Nakamura AJ, Georgakilas AG, Bonner WM. Role of oxidatively induced DNA lesions in human pathogenesis. Mutat Res 2010; 704: 152-159 [PMID: 20060490 DOI: 10.1016/j.mrrev.2009.12.005]
104. McCool KW, Miyamoto S. DNA damage-dependent NF-κB activation: NEMO turns nuclear signaling inside out. Immunol Rev 2012; 246: 311-326 [PMID: 22435563 DOI: 10.1111/j.1600-065X.2012.01101.x]
105. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009; 15: 283-293 [PMID: 19345327 DOI: 10.1016/j.ccr.2009.02.015]
106. Liu X, Ji Q, Ye N, Sui H, Zhou L, Zhu H, Fan Z, Cai J, Li Q. Berberine Inhibits Invasion and Metastasis of Colorectal Cancer Cells via COX-2/PGE2 Mediated JAK2/STAT3 Signaling Pathway. PLoS One 2015; 10: e0123478 [PMID: 25954974 DOI: 10.1371/ journal.pone.0123478]
107. Xiong H, Du W, Sun TT, Lin YW, Wang JL, Hong J, Fang JY. A positive feedback loop between STAT3 and cyclooxygenase-2 gene may contribute to Helicobacter pylori-associated human gastric tumorigenesis. Int J Cancer 2014; 134: 2030-2040 [PMID: 24127267 DOI: 10.1002/ijc.28539]
108. Hein MY, Hubner NC, Poser I, Cox J, Nagaraj N, Toyoda Y, Gak IA, Weisswange I, Mansfeld J, Buchholz F, Hyman AA, Mann M. A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell 2015; 163: 712-723 [PMID: 26496610 DOI: 10.1016/j.cell.2015.09.053]
109. Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 1999; 59: 159-164 [PMID: 9892201]
110. Chung TK, Cheung TH, Wang VW, Yu MY, Wong YF. Microsatellite instability, expression of hMSH2 and hMLH1 and HPV infection in cervical cancer and their clinico-pathological association. Gynecol Obstet Invest 2001; 52: 98-103 [PMID: 11586036 DOI: 10.1159/000052951]
111. Yamamoto H, Itoh F, Nakamura H, Fukushima H, Sasaki S, Perucho M, Imai K. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 2001; 61: 3139-3144 [PMID: 11306499]
112. Watanabe Y, Koi M, Hemmi H, Hoshai H, Noda K. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br J Cancer 2001; 85: 1064-1069 [PMID: 11592780 DOI: 10.1054/bjoc.2001.2037]
113. Hussein MR, Sun M, Tuthill RJ, Roggero E, Monti JA, Sudilovsky EC, Wood GS, Sudilovsky O. Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J Cutan Pathol 2001; 28: 343-350 [PMID: 11437939 DOI: 10.1034/ j.1600-0560.2001.280702.x]
114. Szybka M, Bartkowiak J, Zakrzewski K, Polis L, Liberski P, Kordek R. Microsatellite instability and expression of DNA mismatch repair genes in malignant astrocytic tumors from adult and pediatric patients. Clin Neuropathol 2003; 22: 180-186 [PMID: 12908754]
115. Halford SE, Sawyer EJ, Lambros MB, Gorman P, Macdonald ND, Talbot IC, Foulkes WD, Gillett CE, Barnes DM, Akslen LA, Lee K, Jacobs IJ, Hanby AM, Ganesan TS, Salvesen HB, Bodmer WF, Tomlinson IP, Roylance RR. MSI-low, a real phenomenon which varies in frequency among cancer types. J Pathol 2003; 201: 389-394 [PMID: 14595750 DOI: 10.1002/path.1453]
116. Chiappini F, Gross-Goupil M, Saffroy R, Azoulay D, Emile JF, Veillhan LA, Delvart V, Chevalier S, Bismuth H, Debuire B, Lemoine A. Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers. Carcinogenesis 2004; 25: 541-547 [PMID: 14656944 DOI: 10.1093/carcin/bgh035]
117. Evans SC, Gillis A, Geldenhuys L, Vaninetti NM, Malatjalian DA, Porter GA, Guernsey DL, Casson AG. Microsatellite instability in esophageal adenocarcinoma. Cancer Lett 2004; 212: 241-251 [PMID: 15279904 DOI: 10.1016/j.canlet.2004.03.011]
118. Choy KW, Pang CP, Fan DS, Lee TC, Wang JH, Abramson DH, Lo KW, To KF, Yu CB, Beaverson KL, Cheung KF, Lam DS. Microsatellite instability and MLH1 promoter methylation in human retinoblastoma. Invest Ophthalmol Vis Sci 2004; 45: 3404-3409 [PMID: 15452042 DOI: 10.1167/iovs.03-1273]
119. Kawaguchi K, Oda Y, Takahira T, Saito T, Yamamoto H, Kobayashi C, Tamiya S, Oda S, Iwamoto Y, Tsuneyoshi M. Microsatellite instability and hMLH1 and hMSH2 expression analysis in soft tissue sarcomas. Oncol Rep 2005; 13: 241-246 [PMID: 15643505 DOI: 10.3892/or.13.2.241]
120. Saetta AA, Gigelou F, Papanastasiou PI, Koilakou SV, Kalekou-Greca H, Miliaras D, Michalopoulos NV, Patsouris E. Highlevel microsatellite instability is not involved in gallbladder carcinogenesis. Exp Mol Pathol 2006; 80: 67-71 [PMID: 15963980 DOI: 10.1016/j.yexmp.2005.04.001]
121. Koy S, Plaschke J, Luksch H, Friedrich K, Kuhlisch E, Eckelt U, Martinez R. Microsatellite instability and loss of heterozygosity in squamous cell carcinoma of the head and neck. Head Neck 2008; 30: 1105-1113 [PMID: 18615731 DOI: 10.1002/hed.20857]
122. Perinchery G, Nojima D, Goharderakhshan R, Tanaka Y, Alonzo J, Dahiya R. Microsatellite instability of dinucleotide tandem repeat sequences is higher than trinucleotide, tetranucleotide and pentanucleotide repeat sequences in prostate cancer. Int J Oncol 2000; 16: 1203-1209 [PMID: 10811996 DOI: 10.3892/ ijo.16.6.1203]
123. Arai H, Okudela K, Oshiro H, Komitsu N, Mitsui H, Nishii T, Tsuboi M, Nozawa A, Noishiki Y, Ohashi K, Inui K, Masuda M. Elevated microsatellite alterations at selected tetra-nucleotide (EMAST) in non-small cell lung cancers-a potential determinant of susceptibility to multiple malignancies. Int J Clin Exp Pathol 2013; 6: 395-410 [PMID: 23412080]
124. Catto JW, Azzouzi AR, Amira N, Rehman I, Feeley KM, Cross SS, Fromont G, Sibony M, Hamdy FC, Cussenot O, Meuth M. Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene 2003; 22: 8699-8706 [PMID: 14647464 DOI: 10.1038/sj.onc.1206964]
125. Carethers JM, Jung BH. Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology 2015; 149: 1177-1190. e3 [PMID: 26216840 DOI: 10.1053/j.gastro.2015.06.047]
126. Ashktorab H, Kupfer SS, Brim H, Carethers JM. Racial Disparity in Gastrointestinal Cancer Risk. Gastroenterology 2017; 153: 910-923 [PMID: 28807841 DOI: 10.1053/j.gastro.2017.08.018]